– UK, Cambridge – Sphere Fluidics, a company developing single-cell analysis systems underpinned by its patented pico droplet technology, today announced the appointment of Ken Hitchner as Chairman of its Board of Directors.
About Kenneth Hitchner
With over 30 years in the healthcare industry, Ken brings extensive strategic advisory, M&A, underwriting, and other transactional expertise. He spent much of his 28-year career at Goldman Sachs in the biopharmaceutical and medical device sectors; was a member of the Global Management Committee and Chairman and CEO of Asia Pacific, excluding Japan, from 2013 to 2019. Before this role, Ken was Goldman Sachs’ Global Head of Healthcare Banking and Global Co-Head of TMT Banking. Before joining Goldman Sachs, Ken was a carrier-based fighter bomber pilot for the U.S. Navy. He is currently a Board member of publicly traded Wuxi Biologics and CStone Pharmaceuticals and a senior advisor to Wuxi Apptec. Additionally, Ken is Chairman of HH&L, a healthcare-focused specialty acquisition company listed on the NYSE, and Cydar Medical. He is also a senior advisor to early-stage venture capital firm Antler.
Ken Hitchner said: “Sphere Fluidics is changing the face of cell line development. The Cyto-Mine platform has transformed single-cell analysis and the productivity of biopharmaceutical discovery, maximizing researchers’ productivity in finding rare or valuable cell variants that can lead to a life-changing medicine. I look forward to collaborating with the team as we drive the Company forward in this exciting next phase of commercial growth.”
For more information: https://spherefluidics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
